Introduction: Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.
Methods: A group of experts with academic background and real world experience in mCRC got together. We reviewed the current literature and the insights gained from our real world experience. Based on the same we put together these recommendations.
Recommendations Results: Molecular testing should be done wherever possible. Most of these patients will be treated with a palliative approach. Doublet chemotherapy is a long-standing standard of care. Triplet therapy may be offered where a more aggressive approach is indicated. Combination with anti -vascular endothelial growth factor antibodies and/or anti EGFR antibodies is also considered standard. In the first-line setting, pembrolizumab can be used for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumours; Left and right sided tumours are distinct entities. Combination of chemotherapy and targeted therapy is used as per individual patient and tumour characteristics.Oligometastatic disease can be approached with potentially curative intent. Cytoreductive surgery plus chemotherapy can be offered to selected patients with peritoneal only metastases. Stereotactic body radiation therapy can be used as local therapy for patients with oligometastatic liver only disease who cannot be taken up for surgery. New strategies include induction-maintenance chemotherapy and perioperative chemotherapy. All drugs/ regimen included as standard of care in the first line can also be used in subsequent lines. Specific targetable driver mutation tumours can be treated accordingly with their complementary biological therapy.
Conclusion: Multidisciplinary team management and shared decision making are possible when patient and caregivers choose to become active participants.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888815 | PMC |
http://dx.doi.org/10.1055/s-0044-1791689 | DOI Listing |
Front Pharmacol
February 2025
Organon, Jersey City, NJ, United States.
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars. Hence, this aims to explore the role of real-world evidence on biosimilars by showcasing how real-world evidence studies have contributed to addressing key questions affecting biosimilar market access. We find that the comparable efficacy and safety of a biosimilar and the reference product is corroborated by real-world evidence.
View Article and Find Full Text PDFFront Neurol
February 2025
Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, Netherlands.
Risk Manag Healthc Policy
March 2025
Passionate Healthcare Strategist | Change Leader & Trusted Consultant | Driving Operational Excellence & Innovation in Healthcare and Beyond at Ascend Solutions, Western Region, Saudi Arabia.
Background: The integration of big data analytics in healthcare has become essential for enhancing operational performance, particularly within Emergency Departments (EDs), where efficiency improvements can significantly impact patient satisfaction and resource utilization.
Aim: This study examines the impact of big data analytics on ED performance metrics within Saudi Arabia's Ministry of Health (MOH) hospitals, with a focus on key performance indicators (KPIs) and the effectiveness of the Ada'a Health Program in optimizing ED operations.
Methods: A retrospective observational study was conducted across 10 hospitals in five regions of Saudi Arabia.
BMC Ophthalmol
March 2025
Department of Ophthalmology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK.
Background: Faricimab is a novel anti-vascular endothelial growth factor agent, used to treat patients with neovascular age-related macular degeneration (nAMD). This study assessed efficacy and safety of faricimab in previously treated eyes.
Methods: This retrospective study included previously treated nAMD patients who had received at least three faricimab injections.
BMC Med Educ
March 2025
Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran.
Background: The integration of smart glasses technology in medical education has emerged as a promising approach to enhance medical education specially in clinical setting. Grounded in situational learning theory, smart glasses provide immersive experiences that allow students to engage with real-world clinical scenarios. The purpose of this study is to investigate the application and impact of smart glasses technology in medical education.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!